Described by its investigators as the first use of click chemistry inside patients. A gel was injected into one tumour and an inactive form of doxorubicin was given into a vein, to be switched on at the gel. Doses far above the usual doxorubicin dose were tolerated, but tumours shrank in 2 of 14 sarcoma patients, no more often than with ordinary doxorubicin, and the sponsor stopped the trial.
A multicentre, open-label, non-randomised phase 1/2a study sponsored by Shasqi, registered in September 2019 and started on 1 August 2020 at seven centres in the United States and three in Australia. Each 21-day cycle began with 10 or 20 mL of the biopolymer SQL70 injected into a single lesion, followed by the doxorubicin prodrug SQP33 infused daily. The registry lists nine dose-escalation cohorts from 8 to 315 mg/m2 of SQP33 a day for five days with 10 mL of SQL70, two cohorts with 20 mL, one further cohort at 185 mg/m2 a day (Cohort A) and three phase 2a groups, 53 participants in all.
Phase 1 set out to find the recommended phase 2 dose, which the posted results give as 1250 mg/m2 of SQP33 per cycle. The preprint reporting the whole trial describes 39 phase 1 patients treated at 0.38 to 15 times the standard doxorubicin dose with no dose-limiting toxicity, and 12 times chosen as the recommended dose.
Phase 2a tested that dose in soft tissue sarcoma on three-day and five-day schedules. The registry's response table shows objective responses in 2 of 15 participants: none of 1 in a cohort below the recommended dose, 1 of 2 in the extremity sarcoma group, none of 6 on the three-day schedule and 1 of 6 on the five-day schedule. The preprint reports an unconfirmed objective response rate of 14.3 per cent (2 of 14) and disease control in 71.4 per cent (10 of 14; 95% CI 41.9 to 91.6), with tumour shrinkage in injected and non-injected lesions.
The registry records the study as terminated by the sponsor's decision, with primary completion on 7 September 2023. The preprint gives the reason: the prespecified criterion for continuing, a response rate greater than that of standard doxorubicin, was not met. Across all 53 participants the registry reports 2 deaths from any cause and 15 people with at least one serious adverse event over the one-year reporting period.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
53 enrolled.
2 of 14
Source10 of 14; 95% CI 41.9 to 91.6
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Recommended phase 2 dose of SQP33 (phase 1)primary | Dose escalation with 10 mL SQL70 | 30 | 1250 mg/m2 per cycle | - | - | link |
| Dose escalation with 20 mL SQL70 | 8 | 1250 mg/m2 per cycle | ||||
| Participants with an objective response (phase 2a, RECIST, by MRI) | Cohort A, 185 mg/m2 a day (below the recommended dose) | 1 | 0 participants | - | - | link |
| Phase 2a group 1, extremity soft tissue sarcoma | 2 | 1 participants | ||||
| Phase 2a group 2, three-day schedule | 6 | 0 participants | ||||
| Phase 2a group 2, five-day schedule | 6 | 1 participants | ||||
| Unconfirmed objective response rate, soft tissue sarcoma at the recommended dose (preprint) | SQ3370 phase 2a | 14 | 14.3 percent | - | - | link |
| Disease control rate, soft tissue sarcoma at the recommended dose (preprint) | SQ3370 phase 2a | 14 | 71.4 percent | - | - | link |
It establishes that a click reaction between two separately given substances can be run inside a person, and that capping doxorubicin this way lets far more of it be given. It does not establish that patients do better: the abstract reports no tumour responses, and the trial's phase 2a part later found a response rate comparable to standard doxorubicin.
For a person with sarcoma, this is a treatment that was easier to tolerate than its dose would suggest but did not work better than doxorubicin in the small group tested, and it is not available. For the field, it is the human proof that click activation works as chemistry, which is why the company has moved to versions guided by tumour-binding proteins.
Shares MD Anderson Cancer Center, Sarcomas (soft tissue, bone, GIST) and the tag failure.
Shares MD Anderson Cancer Center and the tag failure.
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Sarcoma Oncology Center, Sant P. Chawla, Sarcomas (soft tissue, bone, GIST).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/